These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 28947947)

  • 1. Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.
    Hoegenauer K; Soldermann N; Zécri F; Strang RS; Graveleau N; Wolf RM; Cooke NG; Smith AB; Hollingworth GJ; Blanz J; Gutmann S; Rummel G; Littlewood-Evans A; Burkhart C
    ACS Med Chem Lett; 2017 Sep; 8(9):975-980. PubMed ID: 28947947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective "activated PI3Kδ syndrome"-targeted therapy with the PI3Kδ inhibitor leniolisib.
    Rao VK; Webster S; Dalm VASH; Šedivá A; van Hagen PM; Holland S; Rosenzweig SD; Christ AD; Sloth B; Cabanski M; Joshi AD; de Buck S; Doucet J; Guerini D; Kalis C; Pylvaenaeinen I; Soldermann N; Kashyap A; Uzel G; Lenardo MJ; Patel DD; Lucas CL; Burkhart C
    Blood; 2017 Nov; 130(21):2307-2316. PubMed ID: 28972011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3Kδ Pathway Dysregulation and Unique Features of Its Inhibition by Leniolisib in Activated PI3Kδ Syndrome and Beyond.
    Cant AJ; Chandra A; Munro E; Rao VK; Lucas CL
    J Allergy Clin Immunol Pract; 2024 Jan; 12(1):69-78. PubMed ID: 37777067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interim analysis: Open-label extension study of leniolisib for patients with APDS.
    Rao VK; Kulm E; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Dalm VA; Trizzino A; Zharankova Y; Webster S; Orpia A; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Relan A; Holland SM; Lenardo MJ; Uzel G
    J Allergy Clin Immunol; 2024 Jan; 153(1):265-274.e9. PubMed ID: 37797893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Pharmacological Characterization of Novel Quinazoline-Based PI3K Delta-Selective Inhibitors.
    Hoegenauer K; Soldermann N; Stauffer F; Furet P; Graveleau N; Smith AB; Hebach C; Hollingworth GJ; Lewis I; Gutmann S; Rummel G; Knapp M; Wolf RM; Blanz J; Feifel R; Burkhart C; Zécri F
    ACS Med Chem Lett; 2016 Aug; 7(8):762-7. PubMed ID: 27563400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of novel pyrrolidineoxy-substituted heteroaromatics as potent and selective PI3K delta inhibitors with improved physicochemical properties.
    Hoegenauer K; Soldermann N; Hebach C; Hollingworth GJ; Lewis I; von Matt A; Smith AB; Wolf RM; Wilcken R; Haasen D; Burkhart C; Zécri F
    Bioorg Med Chem Lett; 2016 Dec; 26(23):5657-5662. PubMed ID: 27816514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of a Potent, Selective, and Orally Available PI3Kδ Inhibitor for the Treatment of Inflammatory Diseases.
    Erra M; Taltavull J; Gréco A; Bernal FJ; Caturla JF; Gràcia J; Domínguez M; Sabaté M; Paris S; Soria S; Hernández B; Armengol C; Cabedo J; Bravo M; Calama E; Miralpeix M; Lehner MD
    ACS Med Chem Lett; 2017 Jan; 8(1):118-123. PubMed ID: 28105286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel quinazolinone derivatives as high potent and selective PI3Kδ and PI3Kδ/γ inhibitors.
    Ma CC; Zhang CM; Tang LQ; Liu ZP
    Eur J Med Chem; 2018 May; 151():9-17. PubMed ID: 29601991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphatidyl Inositol 3-Kinase (PI3K)-Inhibitor CDZ173 protects against LPS-induced osteolysis.
    Wu Z; Li X; Chen X; He X; Chen Y; Zhang L; Li Z; Yang M; Yuan G; Shi B; Chen N; Li N; Feng H; Zhou M; Rui G; Xu F; Xu R
    Front Pharmacol; 2022; 13():1021714. PubMed ID: 36686650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, Synthesis, and Development of Pyrazolo[1,5-
    Stypik M; Michałek S; Orłowska N; Zagozda M; Dziachan M; Banach M; Turowski P; Gunerka P; Zdżalik-Bielecka D; Stańczak A; Kędzierska U; Mulewski K; Smuga D; Maruszak W; Gurba-Bryśkiewicz L; Leniak A; Pietruś W; Ochal Z; Mach M; Zygmunt B; Pieczykolan J; Dubiel K; Wieczorek M
    Pharmaceuticals (Basel); 2022 Jul; 15(8):. PubMed ID: 36015075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of (S)-2-amino-N-(5-(6-chloro-5-(3-methylphenylsulfonamido)pyridin-3-yl)-4-methylthiazol-2-yl)-3-methylbutanamide (CHMFL-PI3KD-317) as a potent and selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor.
    Liang X; Li F; Chen C; Jiang Z; Wang A; Liu X; Ge J; Hu Z; Yu K; Wang W; Zou F; Liu Q; Wang B; Wang L; Zhang S; Wang Y; Liu Q; Liu J
    Eur J Med Chem; 2018 Aug; 156():831-846. PubMed ID: 30053721
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Pearson D; Garnier M; Luneau A; James AD; Walles M
    Xenobiotica; 2019 Aug; 49(8):953-960. PubMed ID: 30215545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term treatment with selective PI3Kδ inhibitor leniolisib in adults with activated PI3Kδ syndrome.
    Rao VK; Kulm E; Grossman J; Buchbinder D; Chong H; Bradt J; Webster S; Šedivá A; Dalm VA; Uzel G
    Blood Adv; 2024 Jun; 8(12):3092-3108. PubMed ID: 38593221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome.
    Rao VK; Webster S; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Conlon N; Coulter T; Dalm VA; Trizzino A; Zharankova Y; Kulm E; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Kucher K; Relan A; Holland SM; Lenardo MJ; Uzel G
    Blood; 2023 Mar; 141(9):971-983. PubMed ID: 36399712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunological characterization of HM5023507, an orally active PI3Kδ/γ inhibitor.
    Cai Y; Yu J; Ren P; He J; Wu Z; Xiao K; Jia H; Wang J; Sai Y; Dai G; Li X; Su W; Ngo K; Castro G; Acton PD; Fung-Leung WP; Edwards JP; Venable J; Rao TS
    Pharmacol Res Perspect; 2020 Feb; 8(1):e00559. PubMed ID: 31956418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INCB040093 Is a Novel PI3K
    Shin N; Li YL; Mei S; Wang KH; Hall L; Katiyar K; Wang Q; Yang G; Rumberger B; Leffet L; He X; Rupar M; Bowman K; Favata M; Li J; Liu M; Li Y; Covington M; Koblish H; Soloviev M; Shuey D; Burn T; Diamond S; Fridman J; Combs A; Yao W; Yeleswaram S; Hollis G; Vaddi K; Huber R; Newton R; Scherle P
    J Pharmacol Exp Ther; 2018 Jan; 364(1):120-130. PubMed ID: 29127109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leniolisib: First Approval.
    Duggan S; Al-Salama ZT
    Drugs; 2023 Jul; 83(10):943-948. PubMed ID: 37256490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. INCB050465 (Parsaclisib), a Novel Next-Generation Inhibitor of Phosphoinositide 3-Kinase Delta (PI3Kδ).
    Yue EW; Li YL; Douty B; He C; Mei S; Wayland B; Maduskuie T; Falahatpisheh N; Sparks RB; Polam P; Zhu W; Glenn J; Feng H; Zhang K; Li Y; He X; Katiyar K; Covington M; Feldman P; Shin N; Wang KH; Diamond S; Li Y; Koblish HK; Hall L; Scherle P; Yeleswaram S; Xue CB; Metcalf B; Combs AP; Yao W
    ACS Med Chem Lett; 2019 Nov; 10(11):1554-1560. PubMed ID: 31749910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. From PIM1 to PI3Kδ via GSK3β: Target Hopping through the Kinome.
    Henley ZA; Bax BD; Inglesby LM; Champigny A; Gaines S; Faulder P; Le J; Thomas DA; Washio Y; Baldwin IR
    ACS Med Chem Lett; 2017 Oct; 8(10):1093-1098. PubMed ID: 29057057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of 5,6,7,8-tetrahydropyrido[4,3-d]pyrimidines to generate a highly selective PI3Kδ inhibitor.
    Hamajima T; Takahashi F; Kato K; Sugano Y; Yamaki S; Suzuki D; Moritomo A; Kubo S; Nakamura K; Yamagami K; Yokoo K; Fukahori H
    Bioorg Med Chem; 2019 Mar; 27(6):1056-1064. PubMed ID: 30755348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.